Lundbeck joins forces with Iambic to leverage AI for drug discovery

Danish CNS specialist Lundbeck (LUND: CO) and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine.

Although no financial terms of the deal were disclosed, Lundbeck said the agreement includes an upfront payment, performance-based milestones, and royalties.

“Iambic’s state-of-the-art platform - including the NeuralPLexer protein-ligand structure prediction technology - will accelerate the generation of novel candidates with a higher probability of success at reaching our patients,” said Tarek Samad, senior vice president, and head of global research at Lundbeck. “The pace at which Iambic can both design molecules in silico and then test them in the laboratory has the potential to unlock compelling neurology targets that have eluded traditional drug discovery methods,” he noted.